Memory Cell Shift Marks the Blood Signature of HTLV-1-Driven Leukemia

Human T-cell lymphotropic virus type 1, or HTLV-1, is a retrovirus that spends its entire life inside CD4-positive T lymphocytes, the helper cells that orchestrate much of the immune response. Most people who carry the virus remain symptom-free for decades, yet a fraction eventually develops adult T-cell leukemia/lymphoma, an aggressive malignancy of the very cells the virus prefers to infect. Understanding what distinguishes the blood of asymptomatic carriers from that of patients with this cancer has been a persistent challenge, in part because the differentiation states of circulating CD4 T cells had never been systematically mapped across the full spectrum of infection. A new cross-sectional study from researchers at the Hospital das Clínicas of the University of São Paulo School of Medicine, published in Virology Journal, now provides that map and reveals a striking rearrangement of the T-cell compartment in patients with the disease.

The research team, led by Jéssica Bilar Cavalcanti and corresponding author Hebert Fabricio Culler, enrolled 117 adults at their single center in São Paulo, Brazil. The cohort comprised 80 asymptomatic HTLV-1 carriers, 21 patients with adult T-cell leukemia/lymphoma, and 16 healthy uninfected controls. Crucially, the investigators also subdivided the carriers according to their presumed route of infection: 51 were thought to have acquired the virus vertically, through breastfeeding, while 29 had presumably acquired it sexually. This design allowed the group to ask two distinct questions at once, namely how T-cell differentiation patterns differ between healthy infection and malignant transformation, and whether the way the virus is transmitted leaves any lasting imprint on the immune cell landscape.

To interrogate these questions, the researchers isolated peripheral blood mononuclear cells and subjected them to multiparameter flow cytometry, a technique that tags individual cells with fluorescent antibodies and allows their identity to be read out at single-cell resolution. Total CD4 T-cell frequency was first measured among viable CD3-positive T cells. The team then partitioned the viable CD3-positive CD4-positive population into five differentiation subsets using a panel of three surface markers: CD45RA, which marks cells that have not yet encountered antigen or have reverted to a naive-like state; CCR7, a chemokine receptor that guides cells to lymph nodes; and CD95, a death receptor that serves as a discriminator of memory lineages. Combinations of these markers defined naive cells, stem cell memory T cells known as TSCM, central memory T cells or TCM, effector memory T cells or TEM, and terminally differentiated effector T cells known as TTE.

Statistical rigor was a notable feature of the analysis. Group comparisons used Kruskal-Wallis tests followed by Dunn’s pairwise tests with Holm adjustment, and the investigators applied false-discovery-rate correction across six outcomes to guard against spurious findings from multiple testing. Because age and sex are known to shape T-cell differentiation, median regression models estimated differences adjusted for these covariates. This layered approach means that the associations reported by the team survived corrections that many immunology studies of this size omit, lending weight to the central conclusion that the differentiation profile of circulating CD4 T cells is genuinely altered in adult T-cell leukemia/lymphoma.

The headline finding concerns the fate of the naive and memory compartments. Patients with ATLL had a median naive-cell frequency of just 2.91 percent, compared with 27.95 percent in asymptomatic carriers and 24.40 percent in healthy controls. Their central memory compartment was similarly collapsed, at 12.30 percent versus 25.35 percent in carriers and 31.85 percent in controls. In the opposite direction, effector memory cells were dramatically expanded in the patients, accounting for a median 49.80 percent of circulating CD4 T cells, roughly three times the 16.15 percent seen in carriers and the 17.80 percent seen in controls. All three of these global comparisons remained significant after false-discovery-rate correction, indicating that they are unlikely to be statistical artifacts.

Covariate adjustment sharpened rather than diluted the signal. After controlling for age and sex, ATLL remained associated with naive-cell frequencies roughly 25 percentage points lower than in asymptomatic carriers and 21.29 points lower than in healthy controls. Central memory frequencies were 12.80 points lower relative to carriers and 16.97 points lower relative to controls, while effector memory frequencies were 34.40 points and 31.85 points higher, respectively. In other words, the malignant state is characterized not by an overall expansion of CD4 T cells but by a qualitative shift in which cells dominate the circulation: long-lived naive and central memory populations contract, and terminally poised effector memory cells take their place.

Two subsets told a quieter story. Stem cell memory T cells, the earliest and most potent self-renewing branch of the memory lineage, showed no significant unadjusted global difference among the groups, and terminally differentiated effector T cells likewise did not differ. The total frequency of CD4 T cells among viable CD3 T cells showed only a nominal difference across groups, with a p-value of 0.0478, and this did not hold up after false-discovery-rate correction or covariate adjustment. The authors interpret this carefully: the pattern in ATLL reflects a redistribution of differentiation states within the circulating CD4 pool rather than a consistent increase in the number of CD4 T cells themselves. That distinction matters, because it suggests the leukemia reshapes the composition of the T-cell compartment even when bulk counts appear unremarkable.

The second major question, whether transmission route leaves an immunological fingerprint, received a negative answer. When the investigators compared asymptomatic carriers presumed to have been infected through breastfeeding with those presumed to have acquired the virus sexually, they found no statistically detectable differences in the distribution of CD4 differentiation subsets between the two groups. This finding is of practical interest in Brazil, which carries one of the highest HTLV-1 burdens in the world and where vertical transmission through breastfeeding is a major public health concern. The result suggests that, at the level of circulating T-cell differentiation measured here, the circumstances of acquisition do not visibly reorganize the carrier’s immune landscape decades later.

Mechanistically, the contraction of naive and central memory cells alongside effector memory expansion fits a picture in which the leukemic clone, derived from virally infected CD4 T cells, displaces or remodels the normal T-cell hierarchy. HTLV-1 persists largely by driving proliferation of infected cells, and viral proteins such as the basic leucine zipper factor HBZ have been implicated in modulating T-cell differentiation and survival. The study was not designed to establish causation, and its cross-sectional design means the observed redistribution could be either a driver or a consequence of malignant transformation. Nevertheless, the consistency of the naive-low, TCM-low, TEM-high signature after rigorous correction, and its independence from age and sex, marks it as a robust correlate of disease state.

The work also demonstrates the value of disciplined flow cytometry practice. The gating strategy relied on viable CD3-positive CD4-positive cells and the three-marker combination of CD45RA, CCR7 and CD95, with fluorescence-minus-one controls referenced in the study’s methods vocabulary to set boundaries between subsets, an approach that reduces subjectivity in defining populations as rare as stem cell memory T cells. Ethical oversight came from the Research Ethics Committee of Hospital das Clínicas, under approved protocol, with written informed consent from all participants. Funded by Brazilian agencies including CAPES, CNPq and FAPESP, the study involved collaboration with Imperial College London and the Instituto de Medicina Tropical of the University of São Paulo. For clinicians, the findings point toward a measurable immunophenotypic signature that could, with further validation, complement existing markers in monitoring progression from silent carriage to leukemia. For virologists, they sharpen the question of how a virus that colonizes the helper T-cell compartment ultimately rewires it, and which of the contracted or expanded subsets offer the most informative targets for early detection and therapeutic intervention.

Subject of Research: Distribution of circulating CD4 T-cell differentiation subsets in HTLV-1 infection and adult T-cell leukemia/lymphoma

Article Title: Circulating CD4 + T-Cell differentiation subsets show a distinct distribution in HTLV-1–associated adult T-Cell leukemia/lymphoma

Article References: Circulating CD4 + T-Cell differentiation subsets show a distinct distribution in HTLV-1–associated adult T-Cell leukemia/lymphoma. (n.d.). https://doi.org/10.1186/s12985-026-03323-x

Image Credits: AI Generated

DOI: 10.1186/s12985-026-03323-x

Keywords: HTLV-1, adult T-cell leukemia/lymphoma, CD4 T cells, T-cell differentiation, effector memory T cells, central memory T cells, naive T cells, flow cytometry, transmission route, retrovirus, immunophenotyping, Virology Journal